Français

The Maritimes includes New Brunswick, Nova Scotia and Prince Edward Island!

Here in the Maritimes, we have an incredible community of volunteers, donors and sponsors, as well as an innovative team of researchers and healthcare professionals. These people are the heart and soul of our organization, and there are so many exciting ways to get involved! Every volunteer, donor, researcher and sponsor helps us to improve the lives of those affected by Crohn’s disease and ulcerative colitis, and brings us closer to finding cures.

Coordinator, Development and Community Engagement, Manitoba
Ashley Clarke
aclarke...crohnsandcolitis...ca
403-700-1729

Crohn's and Colitis Canada Office:
416-920-5035 ext. 340 | 1-800-387-1479

Events

Gutsy Learning Sereies logo on background of a public speaker

Navigating Crohn's and colitis in the Workplace: Empowering Tools for Disclosure and Accommodations

The Gutsy Learning Series (GLS) offers a unique opportunity to learn directly from Canada’s leading experts in inflammatory bowel disease (IBD). Whether you're living with Crohn’s ...

 • 
Virtual
 • 
A family gathered around a child looking at a tablet

Ask the Expert: Caregiving and IBD

Are you supporting someone with inflammatory bowel disease (IBD), or living with IBD while providing care to someone else? You're not alone.  Join our free Ask the Expert event designed to ...

 • 
Virtual - Online
 • 
Remember to bookmark this page.

Crohn’s and Colitis Canada – Maritimes Region mailing address

2110-439 University Avenue
Toronto, ON M5G 1Y8

403-700-1729 1-800-265-1101

Search by Postal Code

News

The Canadian Inflammatory Bowel Disease Research Consortium awards first $1M Pioneer Grant from Takeda Canada

The Canadian Inflammatory Bowel Disease Research Consortium awards first $1M Pioneer Grant from Takeda Canada

Crohn’s and Colitis Canada and Pfizer Canada Announce 2022 Women in IBD Award Recipients

Crohn’s and Colitis Canada and Pfizer Canada Announce 2022 Women in IBD Award Recipients

Health Canada has approved SKYRIZI® (risankizumab) an intravenous and subcutaneous medication treatment for adults with moderately to severely active Crohn's Disease

Health Canada has approved SKYRIZI® (risankizumab) an intravenous and subcutaneous medication treatment for adults with moderately to severely active Crohn's Disease

Send an eCard to Friends or Family Members in Support of Crohn's and Colitis Canada

Send an eCard to Friends or Family Members in Support of Crohn's and Colitis Canada

 18 19 20 21 22 23 24 25 26 27